Objectives: Hepatic arterial infusion (HAI) of cytotoxic chemotherapy is a strategy to deliver high dose of anticancer therapy to liver metastases that derive their blood supply from the hepatic artery. Metastatic melanoma (MM) has a high incidence of liver metastases, with uveal subtype in particular exhibiting a predilection for liver dissemination. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) has demonstrated efficacy in MM and first-pass hepatic metabolism. Therefore, we hypothesized that HAI of nab-paclitaxel would deliver an effective dose of drug to the end organ of interest, with minimal systemic exposure.
BACKGROUND
Metastatic melanoma (MM) is a fatal disease with a rapid systemic dissemination. According to the American Cancer Society, the 5-year survival rate of stage IV melanoma before the widespread use of targeted therapy and checkpoint blockade was 15% to 20%. 1 Although almost all organs can be involved, the most frequent metastatic sites are the liver, bone, and brain. 2, 3 The site of distant metastasis is an important independent predictor of survival in patients with metastatic disease. Melanoma patients with isolated but inoperable liver metastases or liver predominant disseminated disease are potential candidates for hepatic arterial therapy. 3 The overall incidence of liver involvement in MM patients range from 47% to 60%, and nearly half of all uveal melanomas will develop distant metastasis, with a predilection for the liver in virtually all cases. 4, 5 The rationale for liver-directed therapy is based on potential anatomic and physiological characteristics of liver metastases that confer an improvement in therapeutic index by administration of anticancer agents through the hepatic arterial system. 6 Moreover, liver metastases derive their blood supply from the hepatic artery, unlike hepatocytes which are perfused predominantly from the portal vein, making hepatic arterial infusion (HAI) of a therapeutic agent a treatment strategy for patients with unresectable liver metastases. 7 Cytotoxic chemotherapy was historically used to debulk tumor burden, although improvement in overall survival in MM treated with chemotherapies has not been demonstrated. More recently, chemotherapy is sometimes utilized as a means to release neo-antigens in patients who might be bridged to immune therapy. 8, 9 Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) has demonstrated a larger volume of distribution, more rapid clearance, a higher fraction of unbound drug, and higher systemic exposures and maximal concentrations of unbound drug relative to solvent-based paclitaxel, resulting in the ability to deliver more drug over a shorter frame of time and reach greater extent of tissue distribution as a result of a greater first-pass hepatic extraction. [10] [11] [12] [13] In a phase I trial utilizing nab-paclitaxel by HAI, it was demonstrated that doses of ≤ 260 mg/m 2 given for 1 hour every 3 weeks were welltolerated and showed activity in advanced cancer patients with predominant liver metastases. 14 Herein, we report a phase I/II trial of HAI nab-paclitaxel to determine the safety and efficacy of nab-paclitaxel administered through the hepatic artery in patients with MM to the liver.
PATIENTS AND METHODS

Patient Eligibility
Patients with histologic confirmation of MM and documented measurable metastatic disease in the liver ≥ 2 cm in largest dimension were selected. Patients were required to be at least 18 years old, have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, life expectancy of at least 3 months and the ability to understand and willingness to sign an Institutional Review Board approved informed consent. Eligible laboratory criteria included normal serum total bilirubin level, transaminase levels (aspartate aminotransferase and alanine aminotransferase) no higher than 2.5 times the institution upper limit of normal, adequate renal function (creatinine < 1.5 mg/dL), adequate bone marrow function defined as absolute neutrophil count ≥ 1500/mm, platelet count ≥ 100,000/mm 3 , and hemoglobin ≥ 9.0 g/dL. At least 4 weeks must have elapsed from any prior immunotherapy, cytokine, biological vaccine therapy, tumor embolization or radiotherapy before starting on this study. Patients were excluded if they received prior treatment with taxanes or had a history of central nervous system metastasis. The study was performed in accordance with the International Council for Harmonisation.
Study Design
This phase I/II study was conducted at MD Anderson and approved by the MD Anderson Cancer Center Institutional Review Board. Informed consents were obtained from all subjects before enrollment. The primary objective of the phase I portion of the study was to determine the maximum-tolerated dose (MTD) of nab-paclitaxel given via hepatic artery for melanoma liver metastases. Patients meeting eligibility criteria were enrolled in groups of 3 to receive nab-paclitaxel infusion once in every 3 weeks. Four dose groups were planned: 130, 170, 220, and 285 mg/m 2 . Serial measurements of safety were performed at each visit. Prophylactic use of hematopoietic growth factors to manage toxicities was not allowed during cycles 1 and 2, but was allowed during subsequent cycles. Dose-limiting toxicities (DLTs) were graded using CTCAE v3.0 and defined as any of the following: ≥ grade 3 nonhematologic toxicity; grade 3 transaminitis present for ≥ 7 days; grade 3 neutropenia with fever requiring hospitalization for parenteral antibiotics; grade 4 neutropenia lasting ≥ 7 days or complicated by infection; platelet count <25,000 mm 3 . In addition, persistent grade 4 nausea, vomiting, or diarrhea despite optimal symptomatic treatment was considered a DLT if present in the first cycle. Patients who did not have disease progression by investigator-assessed Response Evaluation Criteria In Solid Tumors (RECIST) 1.0 15 at the completion of the first 2 cycles of study continued treatment with nab-paclitaxel therapy and serial measurements of safety and efficacy were performed.
In phase I, 3 patients were treated at a time starting at a dose of 130 mg/m 2 . A 3+3 design was used for dose escalation. MTD was defined as the highest dose for which the incidence of DLT was experienced by no more than 1 of 6 patients in the first cycle. After cycle 1, intrapatient dose escalation was allowed. In phase II, 16 additional patients were treated at the MTD.
Treatment
Enrolled patients were admitted for treatment at MD Anderson Cancer Center on the day of the procedure. Interventional Radiology collaborators received study subjects for percutaneous intra-arterial hepatic catheter placement. The patients were transferred to a hospital bed and nab-paclitaxel was infused via hepatic artery in a volume of 100 to 200 mL (20 mL/ 100 mg of nab-paclitaxel) of normal saline over 30 minutes with monitoring of vital signs before and after the procedure until stabilized. The catheter was removed at the end of the nabpaclitaxel infusion, and subjects were monitored overnight and discharged the following morning. Treatment courses were repeated every 3 weeks if the patient recovered from toxicities.
RESULTS
Demographics
Between February 2009 and January 2013, a total of 30 patients were registered on this study. The mean age of patients was 65 years, and male to female ratio was 1.7: 1. The most common subtype of primary melanoma was uveal (53%), followed by cutaneous (30%), unknown primary (13%), and 1 patient with primary gastrointestinal mucosal melanoma (3%). Because all patients had liver metastasis, lactate dehydrogenase was elevated in nearly all cases and not captured as a demographic factor. Additional metastatic disease at baseline included lung (43%), systemic visceral lymph nodes (43%), soft tissue (20%), locoregional lymph nodes (10%), spleen (10%), kidney (3%), ovaries (3%), and peritoneum (3%) ( Table 1) .
MTD and Toxicities
In the phase I portion, 3 patients received therapy at 130 mg/m 2 dose level, 3 patients received therapy at 170 mg/ m 2 , 3 patients received therapy at 220 mg/m 2 , and 5 patients at 285 mg/m 2 . Frequency of DLTs are noted in Figure 1 . In the group receiving HAI paclitaxel 130 mg/m 2 (n = 3), all the patients were removed from study after 2 cycles of treatment because of rapid tumor progression. In the 170 mg/m 2 (n = 3) cohort, 1 patient was removed for tumor progression, 1 patient removed for ≥ grade 3 nonhematologic toxicity after cycle 1, and 1 patient removed for insurance issues. For the 220 mg/m 2 cohort (n = 3), 2 patients were removed after 2 cycles of treatment for tumor progression; 1 patient was escalated to 285 mg/m 2 until cycle 4, then had tumor progression. In the 285 mg/m 2 cohort (n = 5), 4 patients were removed from the study for tumor progression, and 1 patient was withdrawn for difficulty with compliance.
After review of cumulative toxicities, the 220 mg/m 2 dose was considered the MTD for the phase II portion of the study (Table 2) . Toxicities outside the DLT period with 285 mg/m 2 resulted in frequent dose delays, notably neuropathy and myelosuppression.
In phase II, at the MTD of 220 mg/m 2 , 3 patients were withdrawn for toxicities (1 patient was withdrawn for grade 3 neutropenia with fever requiring hospitalization, 1 patient with grade 3 transaminitis for > 7 d, 1 patient with ≥ grade 3 nonhematologic toxicity) and 14 patients withdrawn for tumor progression (Table 3) .
Treatment Responses
The best responses during the study were identified for each group. In the 130 mg/m 2 group, all three patients had progressive disease (PD); in the 170 mg/m 2 group, 1 patient had stable disease (SD), 1 patient had a partial response (PR) and 1 patient was not evaluable due to insurance denial of scans. In the 220 mg/m 2 group (n = 19), 42% of patients had SD, 5% of patients had PR, and 53% of patients had PD; in the 285 mg/m 2 group (n = 5) 3 patients had SD, and in 2 patients PD was noted ( Table 4) .
As regards the 2 patients with PR, 1 patient was a 76-yearold woman with unknown primary melanoma metastatic to the lungs, lymph nodes, and liver who had received no prior treatment. Her response was predominantly in the liver and mediastinal lymph nodes and lasted for 10 cycles, ultimately discontinued due to notable disease progression in her thoracic cavity and liver, and new disease including brain metastases. She opted for hospice care and symptom control. The second patient was a 66-year-old woman with cutaneous melanoma with a history of subcutaneous and liver metastases. She was also treatment-naïve and received study treatment for 6 cycles with response in the liver and stable disease in her subcutaneous tumors. Treatment was discontinued due to progression of disease as well as increasing neuropathy. Her subsequent treatments included vemurafenib, temozolomide, and ipilimumab.
Overall Survival
All the patients in phases I and II were considered for survival analysis. Twenty-six of 30 patients died at the time of data analysis and 4 patients were still alive. The median survival among all dose levels was 6.5 months and irrespective of primary melanoma. There was no statistically meaningful difference in the median overall survival between dose levels.
DISCUSSION
Landmark analyses demonstrate the 3-year overall survival of MM patients treated with ipilimumab is 21%, and patients Other ≥ Grade 3 Nonhematologic Toxicity
*One patient was removed from study for insurance issues. †Maximum-tolerated dose includes patients in phases I and II portions of study. ‡One patient withdrew consent due to difficulty complying with study schedule. treated with pembrolizumab is 40%. 16, 17 Before the widespread use of these agents, the survival rate for patients with distant metastases from melanoma was poor with a median overall survival of 12 months. 18 Historically, the survival times for patients with lymph node metastases averaged 12 to 15 months, whereas those for patients with liver and bone metastases averaged 3 to 4 months. 2, 3, 18 Local therapy, including surgical resection, radiation, and transcatheter arterial chemoembolization, is largely ineffective for patients with extensive hepatic metastases from melanoma. 19, 20 However, several studies demonstrated that HAI chemotherapy might be a promising therapeutic strategy for liverdominant disease, as this treatment results in higher local drug concentrations than those achieved by IV infusion. 6, 14, 21, 22 This is related to the fact that malignant hepatic lesions derive most of their blood supply from the hepatic artery in contrast to normal hepatic parenchyma, which derive their blood supply from both the hepatic artery and the portal venous circulation. 7 In a phase I study in patients with liver lesions from primary breast and colorectal metastases, the HAI nab-paclitaxel treated patients showed that this regimen was well-tolerated, with no DLTs observed up to the dose level of 260 mg/m 2 over 60-minute administration once every 3 weeks. 14 In our study, the established MTD was 220 mg/m 2 in patients with MM, similar to a previous report by Tsimberidou's group in which the dose was 225 mg/m 2 with paclitaxel not associated with albumin. 21 The best responses to treatment in our study were identified at the MTD in which 42% of the patients had stable disease, and 5% had PR.
The most common cause for drug discontinuation in our study was tumor progression followed by grade 3 febrile neutropenia, and grade 3 transaminitis for > 7 days. This relatively low HAI nab-paclitaxel toxicity profile might be more favorable than that seen with other agents given via HAI in other cancer types such as oxaliplatin and irinotecan. 22 With regard to survival, the median overall survival in our study was 6.5 months among all doses of HAI nab-paclitaxel.
No responses were seen in uveal melanoma patients in this study. Although the utility of cytotoxic chemotherapy is limited in uveal melanoma, 23 hepatic infusion of chemotherapy is thought to increase drug delivery to the organ of interest and allow a higher dose directly to hepatic tumors. The therapeutic agent will then undergo first-pass metabolism in hepatocytes allowing for decreased drug exposure to the systemic circulation. Taxanes have been among the most clinically active in uveal melanoma with disease stabilization reported despite a lack of objective responses. 24 The lack of response to HAI nabpaclitaxel in uveal melanoma patients in this study was disappointing.
Although checkpoint blockade is improving outcomes for patients with MM, many patients still develop resistance to therapy. HAI therapies have shown some antitumor activity in solid tumors, even in heavily pretreated patients with liver metastases. Nab-paclitaxel has demonstrated activity in MM at a dose of 150 mg/m 2 IV on days 1, 8, and 15 every 28 days, with 15% objective response rate reported in a randomized phase III trial against dacarbazine chemotherapy (11% response rate). 25 In that study, median progression-free survival was 4.8 months with nab-paclitaxel and 2.5 months with dacarbazine in a population where only 8% of patients had received prior treatment for MM. There was no statistically significant difference in median overall survival between the 2 arms. The rationale behind HAI delivery of nab-paclitaxel is the delivery of a higher dose of cytotoxic chemotherapy to the hepatic tumor bed than other conventional methods due to first-pass metabolism with IV administration. In this study, while systemic toxicities were low, indicating substantial hepatic metabolism of drug, responses were underwhelming at the MTD, as was overall survival. Given the extensive use of checkpoint blockade in the treatment of MM, there may be a role for HAI delivery of chemotherapy in combination with checkpoint blockade as a means to liberateneo-antigens in patient populations where immunogenicity is thought to be low. This strategy may be especially meaningful in uveal melanoma, where low tumor mutation burden necessitates other means of antigen release. This would require further investigation and would be strengthened by correlative studies. 
